Oncology – Gastrointestinal
Closure of Temporary Ileostomy 2 Versus 12 Weeks After Rectal Resection for Cancer: A Word of Caution from a Prospective, Randomized Controlled Multicenter Trial.
26 Nov, 2021 | 09:42h | UTC
Clinical practice guideline for the treatment of malignant ascites.
25 Nov, 2021 | 10:28h | UTC
Consensus Statement: U.S. Multi-Society Task Force on Colorectal Cancer now suggests average-risk CRC screening begins at age 45.
21 Nov, 2021 | 23:01h | UTCRelated:
State of the Art Review: Screening and prevention of colorectal cancer.
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
ACG Clinical Guidelines: Start colorectal cancer screening at 45
Long-term results of RCT: Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer.
19 Nov, 2021 | 10:15h | UTCChemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Author Interview: Chemoradiotherapy Plus Induction or Consolidation Chemotherapy for Locally Advanced Rectal Cancer – JAMA Oncology
Commentary on Twitter
Secondary analysis of 311 pts on ARO-12 trial of variant approaches to total neoadjuvant therapy (TNT) w/combo of chemo & concurrent chemoradiation (CRT) for rectal cancer shows best results w/up-front CRT then chemo & resection led to best results https://t.co/7cpv5cb1Fr #CRCSM pic.twitter.com/bxfz9Fi5OB
— JAMA Oncology (@JAMAOnc) November 18, 2021
Nursing care for oncologic patients undergoing surgery using an enhanced recovery approach.
17 Nov, 2021 | 08:22h | UTCOncologic Surgical Care Using an Enhanced Recovery Approach – AACN Advanced Critical Care
News release: Enhanced Recovery Approach Changes Care for Surgical Oncology Patients – American Association of Critical-Care Nurses
Related: Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Among patients with cancer who received decompressive G-tubes for nutrition or malignant bowel obstruction, nearly half presented with stage IV disease and died within one month of placement.
12 Nov, 2021 | 09:55h | UTCCommentary: Risks and Benefits Associated With Gastrostomy Tubes for Patients With Cancer – The ASCO Post
RCT: One-time flexible sigmoidoscopy screening is associated with long-term reduction in colorectal cancer incidence and mortality.
10 Nov, 2021 | 07:04h | UTCCommentaries:
Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors.
9 Nov, 2021 | 01:04h | UTC
Commentary on Twitter
#Neuroendocrine tumors are heterogeneous with a complex treatment landscape. This #JCOOP Clinical Review discusses optimal management of #NET and key patient/tumor characteristics that can guide treatment selection https://t.co/zZF36E93w8 pic.twitter.com/2xqwOlwIvw
— Journal of Clinical Oncology (@JCO_ASCO) October 28, 2021
M-A: Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer.
7 Nov, 2021 | 20:07h | UTC
Review: Clinical management of pancreatic premalignant lesions.
31 Oct, 2021 | 19:56h | UTCClinical Management of Pancreatic Premalignant Lesions – Gastroenterology
RCT: Laparoscopic vs. open distal gastrectomy for locally advanced gastric cancer.
26 Oct, 2021 | 01:40h | UTCLaparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Commentary on Twitter
It is not clear whether laparoscopic (LDG) and open distal gastrectomy (ODG) produce similar long-term outcomes in advanced #gastriccancer. CLASS-01 trial firstly shows LDG results in similar 5-year OS compared to ODG in advanced gastric cancer https://t.co/uUBcLFeqsY
— JAMA Surgery (@JAMASurgery) October 20, 2021
RCT: Among patients with metastatic colorectal cancer, those randomized to systemic treatment alone had lower sixty-day mortality compared to those randomized to primary tumor resection followed by systemic treatment.
12 Oct, 2021 | 00:01h | UTCSixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment: The CAIRO4 Phase 3 Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Editorial: Primary Tumor Resection and Patients With Asymptomatic Colorectal Cancer and Nonresectable Metastases: Results of Recent Randomized Trials – JAMA Surgery (free for a limited period)
Commentary: Systemic Therapy Alone Bests Surgical Tx for Metastatic CRC – BreakingMed
Commentary on Twitter
Early mortality in patients with colorectal cancer and unresectable metastases randomized to primary tumor resection followed by systemic treatment is considerably higher than early mortality in patients randomized to systemic treatment only https://t.co/SyfYjmDU7i @DaveKruijssen
— JAMA Surgery (@JAMASurgery) October 11, 2021
RCT: Neurolytic splanchnic nerve block and pain relief, survival, and quality of life in unresectable pancreatic cancer.
30 Sep, 2021 | 10:16h | UTC
Commentary on Twitter
Neurolytic Splanchnic Nerve Block and Pain Relief, Survival, and Quality of Life in Unresectable Pancreatic Cancer: A Randomized Controlled Trial https://t.co/xa9sPAdQu1 pic.twitter.com/gi74fdDSfl
— Anesthesiology journal (@_Anesthesiology) August 30, 2021
Gastrointestinal stromal tumors: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.
30 Sep, 2021 | 10:11h | UTC
State of the Art Review: Screening and prevention of colorectal cancer.
16 Sep, 2021 | 10:01h | UTCScreening and prevention of colorectal cancer – The BMJ (free for a limited period)
Related:
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
ACG Clinical Guidelines: Start colorectal cancer screening at 45
Guidelines for the surveillance and survivorship care of patients after curative treatment of colon and rectal cancer.
16 Sep, 2021 | 09:52h | UTC
Commentary on Twitter
Clinical Practice Guidelines – Surveillance and Survivorship shown in #DCRJournal visual abstract by @ianmpaquette @JMigaly @ASCRS_1. What do you think? https://t.co/e3kADOerpq@JISBMD @ConorDelaneyMD @justinmaykel @KarimAlavi @KyleCologne @dubaicolorectal @SamAtallahMD pic.twitter.com/wOhu0Mby60
— DCRjournal (@DCRjournal) May 9, 2021
Consensus Guideline: Liver transplantation for non-resectable colorectal liver metastases.
16 Sep, 2021 | 09:50h | UTCLiver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines – The Lancet Gastroenterology & Hepatology (free registration required)
Commentary on Twitter
New online – Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelineshttps://t.co/oZL4X4h7VS@IHPBA @gbonneysurg @eahpba @_ilts_#livertwitter #APHPBA_2021 pic.twitter.com/g6rrVclV5h
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) September 8, 2021
RCT: Effect of Camrelizumab vs. placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma.
15 Sep, 2021 | 08:51h | UTCEffect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma—Renewed Enthusiasm and a Lingering Challenge – JAMA Oncology (free for a limited period)
Commentary on Twitter
Among patients with advanced or metastatic esophageal squamous cell carcinoma, the addition of camrelizumab to chemotherapy, compared with placebo and chemotherapy, significantly improved overall survival and progression-free survival https://t.co/DAlhmtgvv1
— JAMA (@JAMA_current) September 14, 2021
Review: Cholangiocarcinoma.
10 Sep, 2021 | 05:02h | UTCCholangiocarcinoma – Nature Reviews Disease Primers (free for a limited period)
Infographic: Cholangiocarcinoma
Commentary on Twitter
Get Primed on #Cholangiocarcinoma with our NEW PrimeView! FREE to download this week! https://t.co/xw8yl29QI4 pic.twitter.com/JKtL6NqnlS
— Nature Reviews Disease Primers (@DiseasePrimers) September 9, 2021
Pancreatic Cancer: A Review.
9 Sep, 2021 | 08:51h | UTCPancreatic Cancer: A Review – JAMA (free for a limited period)
Antibiotics use is linked to increased risk of subsequent colorectal cancer.
7 Sep, 2021 | 21:25h | UTCCommentaries:
Antibiotics linked to increased risk of colon cancer – Umea University
Study links antibiotics use and increased subsequent risk of colorectal cancer – MedicalResearch.com
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localized colon cancer.
26 Aug, 2021 | 08:33h | UTC
Cohort study: Association of incomplete polyp removal with risk of postcolonoscopy colorectal cancer.
17 Aug, 2021 | 08:43h | UTCOriginal study: Recurrence of Colorectal Neoplastic Polyps After Incomplete Resection – Annals of Internal Medicine (link to abstract – $ for full-text)
Global Incidence and Mortality of Gastric Cancer, 1980-2018
13 Aug, 2021 | 08:45h | UTCGlobal Incidence and Mortality of Gastric Cancer, 1980-2018 – JAMA Network Open
Cystic pancreatic lesions: MR imaging findings and management.
11 Aug, 2021 | 08:21h | UTCCystic pancreatic lesions: MR imaging findings and management – Insights into Imaging
Related:
Recommendations for the management of incidental pancreatic findings in adults.
Pancreatic cystic neoplasms: a review of current recommendations for surveillance and management
Management of Pancreatic Cystic Lesions
Consensus Recommendations: Diagnosis and Surveillance of Incidental Pancreatic Cystic Lesions
Review: Pancreatic Cystic Lesions
Guidelines on pancreatic cystic neoplasms